Rua Bioscience Limited logo

Rua Expands Global Reach with UK Distribution Agreement

Operational Update14 December 2023RUAHealthcare

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



FOR PUBLIC RELEASE

NZX Limited

Wellington


14

th

December 2023


Rua Bioscience Expands Global Reach with UK Distribution Agreement


Rua Bioscience is thrilled to announce another milestone in its export strategy with the

signing of a two-year distribution agreement with Target Healthcare, a pharmaceutical

distributor based in the United Kingdom.


This agreement marks a crucial step in Rua Bioscience’s commitment to broadening its

international presence and ensuring the accessibility of its premium medicinal cannabis

products on a global scale. Leveraging the extensive network of Target Healthcare, Rua

Bioscience aims to distribute its products across the United Kingdom, capitalising on this

rapidly growing medicinal cannabis market.


Paul Naske, CEO of Rua Bioscience, commented on this strategic agreement, stating: “This

partnership with Target Healthcare is a significant step in the journey of our company. It

represents a crucial step in establishing our brand and cultivating a robust presence in the

UK medicinal cannabis market.” Mr. Naske further emphasised that this strategic move

initiates a series of regulatory milestones, with anticipated revenues expected in the UK

market by the conclusion of 2024.


Target Healthcare is an ideal distribution partner for Rua Bioscience, focusing specifically on

the niche segment of the pharmaceutical sector where medicinal cannabis holds a

significant position.


Rua Bioscience remains focused on its strategy of establishing distribution channels in key

export markets and distributing our unique Tairawhiti east coast cannabis varieties in these

markets.


About Target Healthcare


Target Healthcare is a prominent pharmaceutical distributor in the United Kingdom,

specialising in the supply and distribution of pharmaceutical and healthcare products,

particularly within the “specials” category, referring to unlicensed medicines.


ENDS


The person who authorised this announcement:

Paul Naske,

Chief Executive Officer


ANNOUNCEMENT


PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com

For shareholder enquiries please visit www.ruabio.com or contact:

info@ruabio.com

0800 RUABIO

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.